Michael Curtis, eGenesis CEO
October 11, 2023 11:18 AM EDT
R&D
Cell/Gene Tx

eGe­n­e­sis brings kid­ney xeno­trans­plants clos­er to the clin­ic

Ayisha Sharma

News Reporter

eGe­n­e­sis’ ge­net­i­cal­ly mod­i­fied pig kid­ney trans­plant pro­gram reached pre­clin­i­cal proof-of-con­cept in a mon­key mod­el, and the com­pa­ny is in dis­cus­sions with the FDA about what …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times